Tyverb still not cost-effective for breast cancer, says NICE
This article was originally published in Scrip
Executive Summary
NICE, the UK's National Institute for health and Clinical Excellence, maintains that GlaxoSmithKline's Tyverb (lapatinib) is not cost-effective and should not be used to treat previously treated women with advanced or metastatic breast cancer on the NHS in England and Wales.